MX2023014326A - Peptidos y metodos de uso. - Google Patents

Peptidos y metodos de uso.

Info

Publication number
MX2023014326A
MX2023014326A MX2023014326A MX2023014326A MX2023014326A MX 2023014326 A MX2023014326 A MX 2023014326A MX 2023014326 A MX2023014326 A MX 2023014326A MX 2023014326 A MX2023014326 A MX 2023014326A MX 2023014326 A MX2023014326 A MX 2023014326A
Authority
MX
Mexico
Prior art keywords
peptides
methods
synthetic
peptide
neutrophils
Prior art date
Application number
MX2023014326A
Other languages
English (en)
Spanish (es)
Inventor
Neel K Krishna
Kenji Cunnion
Ulrich Thienel
Original Assignee
Realta Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Realta Life Sciences Inc filed Critical Realta Life Sciences Inc
Publication of MX2023014326A publication Critical patent/MX2023014326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/12011—Astroviridae
    • C12N2770/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2023014326A 2021-06-01 2022-05-31 Peptidos y metodos de uso. MX2023014326A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195401P 2021-06-01 2021-06-01
US202163279423P 2021-11-15 2021-11-15
PCT/US2022/031559 WO2022256304A1 (en) 2021-06-01 2022-05-31 Peptides and methods of use

Publications (1)

Publication Number Publication Date
MX2023014326A true MX2023014326A (es) 2023-12-13

Family

ID=84323526

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014326A MX2023014326A (es) 2021-06-01 2022-05-31 Peptidos y metodos de uso.

Country Status (10)

Country Link
US (1) US20240209036A1 (https=)
EP (1) EP4346866A4 (https=)
JP (1) JP2024522988A (https=)
KR (1) KR20240016323A (https=)
AU (1) AU2022286333A1 (https=)
BR (1) BR112023024988A2 (https=)
CA (1) CA3215620A1 (https=)
IL (1) IL308683A (https=)
MX (1) MX2023014326A (https=)
WO (1) WO2022256304A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022094372A1 (en) * 2020-11-02 2022-05-05 Realta Life Sciences, Inc. Peptides and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10005818B2 (en) * 2010-07-21 2018-06-26 Realta Holdings, Llc Derivative peptide compounds and methods of use
JP6698276B2 (ja) * 2012-01-16 2020-05-27 アトックス バイオ リミテッド 細菌感染の治療用の合成ペプチド
LT3286181T (lt) * 2015-04-22 2021-04-26 Rigel Pharmaceuticals, Inc. Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
EP3740074B1 (en) * 2018-01-09 2024-11-06 ReAlta Holdings, LLC Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Also Published As

Publication number Publication date
EP4346866A4 (en) 2025-03-19
CA3215620A1 (en) 2022-12-08
AU2022286333A1 (en) 2023-11-02
KR20240016323A (ko) 2024-02-06
AU2022286333A9 (en) 2023-11-16
IL308683A (en) 2024-01-01
JP2024522988A (ja) 2024-06-25
BR112023024988A2 (pt) 2024-02-20
EP4346866A1 (en) 2024-04-10
WO2022256304A1 (en) 2022-12-08
US20240209036A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
CL2020001262A1 (es) Plataforma de presentación en endosporas basadas en paenibacillus, productos y métodos relacionados.
PE20190335A1 (es) Receptores de celulas t
CL2020000039A1 (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes. (divisional solicitud 201700647)
AR120563A1 (es) Receptores de antígeno quimérico cd19 y cd22 y sus usos
CO2018011668A2 (es) Neoantígenos y métodos de su uso
CL2018003322A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128)
MX2022001299A (es) Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
DOP2017000171A (es) Proteínas de unión a icos.
CU20170112A7 (es) Variantes de polipeptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, así como procedimientos para la división de toxinas de fusarium
CO2018013104A2 (es) Polipéptidos de fusión cd40l-fc y sus métodos de uso
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
MX385674B (es) Composiciones para modular la expresion de c9orf72.
GT201700224A (es) Proteína de unión a rgma y su uso
CL2024000378A1 (es) Anticuerpos anti-npr1 y usos de los mismos.
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
MX2023014326A (es) Peptidos y metodos de uso.
CL2020002246A1 (es) Expresión de proteína de superficie a neumocócica (pspa)
MX2022007919A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
MX2021007354A (es) Polipeptidos con actividad fitasica.
MX2025005382A (es) Fago sintético con proteínas de espicula de cola de fago recombinantes y métodos relacionados
CL2020002507A1 (es) Variantes de lfa3 y composiciones y usos de las mismas
BR112023005783A2 (pt) Peptídeos e métodos de uso
PE20190967A1 (es) Aislados modificados de streptomyces fungicidicus y su uso
CL2020003220A1 (es) Nueva proteína con propiedades antiinflamatorias
CO2020008885A2 (es) Arilsulfatasa a purificada y composiciones de la misma